However, MEK inhibition alone is reported to be sufficient to suppress the metastatic spread of Pten-deleted and KRas activated stem/progenitor murine prostate cancer cells orthotopically transplanted in vivo, similarly to combined mTORC1 and MEK inhibition [101]. The gene discussed is PTEN; the disease is prostate carcinoma.